News & Events
Combinostics is pleased to announce the closure of a €3.9M series A funding round to extend the company’s cNeuro platform in the US and Asia.
Combinostics is pleased to announce an exclusive partnership with Nihon Medi-Physics to develop and market the cNeuro platform in Japan.
Three peer-reviewed, scientific journals have published articles that describe the use of the cNeuro platform for dementias and other cognitive disorders.
Combinostics has been selected to join the 2019 MassChallenge HealthTech cohort which represents the most innovative technologies advancing health and improving the overall patient experience.